1Watanabe H, Kanzaki H. Bcl-2 and Fas expression in eutopic and ectopic human endometrium during the menstrual cycle in relation to endometrial cell apoptosis [ J ]. Am J Obstet Gynecol, 1997,176 (2) :360 - 368.
2Wanger KU, Krempler A, Qi Y, et al. Tsg101 is essential for cell growth, proliferation, and cell survival of embryonic and adult tissues[J]. Mol Cell Biol,2003,23( 1 ) :150 - 162.
3Ohta M,Inoue H,Cotticelli MG, et al. The FHIT gene,spanning the chromosome 3P14.2 fragile site and renal carcinoma-associated t ( 3 ;8 ) breakpoint,is abnormal in digestive tract cancers [ J ]. Cell,1996,84(4) :587 -597.
4Sozzi G,Veronese ML,Negrini M,et el. The FHIT gene at 3p14. 2 is abnormal in lung cancer[ J]. Cell,1996,85(1) :17 -26.
5de Fraipont F, Moro-Sibilot D, Michelland, et al. Promoter methylation of genes in bronchial lavages: a marker for early diagnosis of primary and relapsing non-small cell lung cancer? [J]. Lung Cancer, 2005, 50(2) :199 -209.
6Pylkkanen L,Wolff H, Stjemvall T,et al. Reduced FHIT protein expression and loss of heterozygosity at FHIT gene in turnouts from smoking and asbestos-exposed lung cancer patients [ J ]. Int J Oncol,2002,20 ( 2 ) :285 - 290.
7Dano L, Guilly MN, Moleris M, et al. CGH analysis of radon-induced rat lung tumors indicates similarities with human lung cancers [ J ]. Genes Chromosomes Cancer,2000,29 ( 1 ) : 1 - 8.
8Kowara R, Karaozyn HA, Fivash J, et al. In vitro inhibition of the enzymatic activity of tumor suppressor FHIT gene product by carcinogenic transition metals [ J ]. Chem Res Toxicol, 2002, 15 (3) :319 -325
9Chizhikov V, Chikina S, Gasparian A, et al. Molecular follow-up of preneopla stic lesions in bronchial epithelium of former Chernobyl clean-up workers [ J ]. Oncogene, 2002,21 ( 15 ) : 2398 - 2405.
10Stein CK, Glover TW, Palmer JL, et al. Direct correlation between FRA3B expression and cigarette smoking[ J]. Genes Chromosomes Cancer,2002,34 ( 3 ) :333 - 340.
2Ganti AK,Weir AB,Hurria A. Treatment of non-small cell lung cncer in the older patient[J].J Natl Compr Canc Netw,2012,(2):230-239.
3Fang G,Brooks JM,Chrischilles EA. Apples and oranges?Interpretations of risk adjustment and instrumental varia-ble estimates of intended treatment effects using observa-tional data[J].{H}American Journal of Epidemiology,2012,(1):60-65.
4Berghmans T,Pasleau F,Paesmans M. Surrogate mark-ers predicting overall survival for lung cancer:ELCWP recom-mendations[J].{H}European Respiratory Journal,2012,(1):9-28.
5Maniwa T,Okumura T,Isaka M. Recurrence of me-diastinal node cancer after lobe-specific systematic nodal dissection for non-small-cell lung cancer[J].Eur J Cardio-thor Surg,2013,(1):e59-e64.
6Darling GE,Allen MS,Decker PA. Randomized trial of mediastinal lymph node sampling versus complete lymphadenectomy during pulmonary resection in the pa-tient with N0 or N1(less than hilar) non-small cell carci-noma:Results of the American College of Surgery Oncol-ogy Group Z0030 Trial[J].{H}Journal of Thoracic and Cardiovascular Surgery,2011,(3):662-670.
